Consider OPT and the jump it had post successful phase 2 trial...there is no reason that bot couldn't do the same. Similar MC.
One could certainly argue that bot has a much superior market opportunity in acne should the drug btx1503 be shown to be effective...nevermind the other drugs in the pipeline.
- Forums
- ASX - By Stock
- BOT
- LEAD PRODUCT: BTX 1503 (MODERATE TO SEVERE ACNE) - Phase 2 clinical trial
LEAD PRODUCT: BTX 1503 (MODERATE TO SEVERE ACNE) - Phase 2 clinical trial, page-18
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
32.0¢ |
Change
-0.005(1.54%) |
Mkt cap ! $581.5M |
Open | High | Low | Value | Volume |
32.5¢ | 33.0¢ | 32.0¢ | $1.058M | 3.280M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 147750 | 32.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.5¢ | 632850 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 147750 | 0.320 |
22 | 742217 | 0.315 |
27 | 827188 | 0.310 |
11 | 272208 | 0.305 |
28 | 366102 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 632850 | 6 |
0.330 | 90273 | 5 |
0.335 | 193342 | 5 |
0.340 | 408713 | 7 |
0.345 | 406365 | 7 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |